NCT04959903View on ClinicalTrials.gov

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

May 31, 2027

Conditions
Hematological Malignancies
Interventions
BIOLOGICAL

Allogeneic T cell progenitors, cultured ex-vivo

Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (MSKCC), New York

All Listed Sponsors
lead

Smart Immune SAS

INDUSTRY